Baylor University Medical Center

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article Association between event-free survival and overall survival in early-stage triple-negative breast cancer (2024) Huang M, Fasching P, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al. Journal article, Review article Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024) Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, et al. Journal article Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis (2023) Cortes J, Haiderali A, Huang M, Pan W, Schmid P, Akers KG, Park JE, et al. Journal article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY (2023) Balmaña J, Fasching P, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, et al. Journal article Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer (2023) Jhaveri K, O’Shaughnessy J, Fasching PA Journal article Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States (2023) Huang M, Fasching P, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, et al. Journal article Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1 (2022) Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, et al. Journal article Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation (2022) Montano-Loza AJ, Ronca V, Ebadi M, Hansen BE, Hirschfield G, Elwir S, Alsaed M, et al. Journal article Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis (2021) Gelmon KA, Fasching P, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, et al. Journal article